PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.

Scientific Reports 2016 September 13 [Link] Kanteti R, Riehm JJ, Dhanasingh I, Lennon FE, Mirzapoiazova T, Mambetsariev B, Kindler HL, Salgia R Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer that is commonly associated with prior asbestos exposure. Receptor tyrosine kinases (RTKs) such as MET and its downstream target PI3K are overexpressed and activated…

Read More

Quercetin and Cisplatin combined treatment altered cell cycle and mitogen activated protein kinase expressions in malignant mesotelioma cells

BMC Complementary and Alternative Medicine 2016 August 11 [Link] Demiroglu-Zergeroglu A, Ergene E, Ayvali N, Kuete V, Sivas H Abstract BACKGROUND: Malignant mesothelioma is a locally aggressive and highly lethal neoplasm of pleural, peritoneal and pericardial mesothelial cells without successful therapy. Previously, we reported that Quercetin in combination with Cisplatin inhibits cell proliferation and activates…

Read More

Common Fluorescence In Situ Hybridization Applications in Cytology

Archives of Pathology & Laboratory Medicine 2016 August 4 [Epub ahead of print] [Link] Savic S, Bubendorf L Abstract CONTEXT: -Fluorescence in situ hybridization (FISH) is a well-established method for detection of genomic aberrations in diagnostic, prognostic, and predictive marker testing. OBJECTIVE: -To review common applications of FISH in cytology. DATA SOURCES: -The published literature…

Read More

c-Met expression and MET amplification in malignant pleural mesothelioma

Annals of Diagnostic Pathology 2016 August 23 [Epub 2016 April 30] [Link] Bois MC, Mansfield AS, Sukov WR, Jenkins SM, Moser JC, Sattler CA, Smith CY, Molina JR, Peikert T, Roden AC Abstract c-Met is a receptor tyrosine kinase shown to be overexpressed in malignant pleural mesothelioma (MPM). Whereas MET mutations have been identified in…

Read More

SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM)

Journal of Thoracic Oncology 2015 February [Link] Ou SH, Moon J, Garland LL, Mack PC, Testa JR, Tsao AS, Wozniak AJ, Gandara DR. Abstract Introduction The PI3K/Akt/mammalian target of rapamycin pathway is activated in a majority of malignant pleural mesotheliomas (MPM). We evaluated the activity of everolimus, an oral mammalian target of rapamycin inhibitor, in…

Read More

Synergistic Activity of the c-Met and Tubulin Inhibitor Tivantinib (ARQ197) with Pemetrexed in Mesothelioma Cells

Current Drug Targets 2014 December 5 [Epub ahead of print] [Link] Leon LG, Gemelli M, Sciarrillo R, Avan A, Zucali PA, Funel N, Santoro A, Giovannetti E. Abstract Malignant pleural mesothelioma (MPM) is a lethal disease with scarce therapeutic options, and preclinical studies on new targeted-agents are warranted. Because previous studies reported high c-Met expression…

Read More

Sphingosine Suppresses Mesothelioma Cell Proliferation by Inhibiting PKC-δ and Inducing Cell Cycle Arrest at the G(0)/G(1) Phase

Cell Physiol Biochem. 2012 Sep 20;30(4):995-1004. [Epub ahead of print] [Link] Okuwa H, Kanno T, Fujita Y, Gotoh A, Tabata C, Fukuoka K, Nakano T, Nishizaki T. Division of Bioinformation, Department of Physiology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Japan. Abstract Background/Aims: Sphingosine regulates cellular differentiation, cell growth, and apoptosis. The present study aimed…

Read More